×

Sign In

Search
Home

AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare diseases portfolio

By Thomson Reuters Mar 14, 2024 | 2:19 AM

(Reuters) – Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.

(Reporting by Eva Mathews in Bengaluru; Editing by Savio D’Souza)

Australia's Wong urges Myanmar generals to take a different path and end conflict

Vietnam's Jan-July foreign investment inflows up 8.4% y/y at $12.55 billion

China's industrial profits post faster gains in June despite faltering economy

Olympics-South Korea expresses regret after its athletes introduced as North Korea at opening ceremony

China's H1 industrial profits rise 3.5% y/y

US union and Apple reach tentative labor agreement

Privacy Policy
Terms Of Service

Midwest Communications, Inc.

Copyright © 2024. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.